drugset / Trial / NCT05950997
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
Recruiting
89 enrolled
The First Affiliated Hospital with Nanjing Medical University
AstraZeneca · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, prospective study to assess the efficacy and safety of acalabrutinib combined with obinutuzumab in subjects with previously untreated chronic lymphocytic leukemia.
Timeline
- Start
- 2024-04-16
- Primary completion
- 2026-05-31
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 100 mg | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |